A Single Dose of an Inhibitor of Cyclooxygenase 2, Meloxicam, Administered Shortly after Irradiation Increases Survival of Lethally Irradiated Mice

This study extends earlier findings of the authors demonstrating that meloxicam, a selective inhibitor of cyclooxygenase 2, supports hematopoietic recovery in sublethally irradiated mice and is radioprotective when given before irradiation. We report here that when meloxicam was administered in a si...

Full description

Saved in:
Bibliographic Details
Published in:Radiation research 2011-08, Vol.176 (2), p.269-272
Main Authors: Hofer, M., Pospíšil, M., Dušek, L., Hoferová, Z., Weiterová, L.
Format: Article
Language:English
Subjects:
Animals
Colony stimulating factors
Cyclooxygenase 2 - metabolism
Cyclooxygenase 2 Inhibitors - administration & dosage
Cyclooxygenase 2 Inhibitors - pharmacology
Dose-Response Relationship, Drug
Granulocyte Colony-Stimulating Factor - blood
Hematopoiesis
Irradiation
Lethal dose
Male
Medical treatment
Mice
Prostaglandins
Radiation damage
Radiation dosage
Radiation-Protective Agents - administration & dosage
Radiation-Protective Agents - pharmacology
Radiotherapy
SHORT COMMUNICATION
Space life sciences
Survival Analysis
Thiazines - administration & dosage
Thiazines - pharmacology
Thiazoles - administration & dosage
Thiazoles - pharmacology
Time Factors
Whole-Body Irradiation - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study extends earlier findings of the authors demonstrating that meloxicam, a selective inhibitor of cyclooxygenase 2, supports hematopoietic recovery in sublethally irradiated mice and is radioprotective when given before irradiation. We report here that when meloxicam was administered in a single dose 1 h after a lethal 9-Gy whole-body dose, an increased 30-day survival was achieved. Additional studies showed that administration of meloxicam 24 h after lethal irradiation is ineffective and its repeated administration deleterious. Possible mechanisms of the therapeutic effects of meloxicam administered early after irradiation are discussed.
ISSN:0033-7587
1938-5404
DOI:10.1667/RR2614.1